Adverum Biotechnologies, Inc. (ADVM)
NASDAQ: ADVM · Real-Time Price · USD
4.260
+0.430 (11.23%)
At close: Apr 2, 2025, 4:00 PM
4.270
+0.010 (0.23%)
After-hours: Apr 2, 2025, 6:16 PM EDT
Adverum Biotechnologies Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2014 - 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2014 - 2018 |
| Cash & Equivalents | 92.85 | 75 | 68.43 | 34.2 | 62.42 | 65.9 | Upgrade
|
| Short-Term Investments | 60.39 | 21.53 | 117.16 | 270.99 | 367.31 | 100.14 | Upgrade
|
| Cash & Short-Term Investments | 153.24 | 96.53 | 185.59 | 305.19 | 429.73 | 166.04 | Upgrade
|
| Cash Growth | 30.88% | -47.99% | -39.19% | -28.98% | 158.82% | -19.04% | Upgrade
|
| Receivables | - | - | - | 5.71 | - | - | Upgrade
|
| Prepaid Expenses | 7.84 | 6.25 | 5.01 | 6.25 | 4.71 | 9.84 | Upgrade
|
| Total Current Assets | 161.08 | 102.77 | 190.6 | 317.15 | 434.44 | 175.87 | Upgrade
|
| Property, Plant & Equipment | 62.91 | 67.03 | 113.86 | 119.06 | 47.1 | 45.85 | Upgrade
|
| Other Long-Term Assets | 10.39 | 3.21 | 3.92 | 3.52 | 1.03 | 1.01 | Upgrade
|
| Total Assets | 234.38 | 173.01 | 308.37 | 439.73 | 482.57 | 222.73 | Upgrade
|
| Accounts Payable | 2.11 | 1.92 | 2.24 | 1.39 | 2.81 | 4.1 | Upgrade
|
| Accrued Expenses | 13.66 | 11.76 | 16.1 | 14.71 | 12.26 | 8.64 | Upgrade
|
| Current Portion of Long-Term Debt | - | - | - | - | - | 0.1 | Upgrade
|
| Current Portion of Leases | 10.66 | 10.41 | 13.24 | 1.89 | 4.47 | 4.03 | Upgrade
|
| Current Income Taxes Payable | - | 0.1 | 0.25 | 1.32 | 0.04 | - | Upgrade
|
| Other Current Liabilities | 1.23 | 0.73 | 0.42 | 2.02 | 1.29 | 2.54 | Upgrade
|
| Total Current Liabilities | 27.66 | 24.91 | 32.25 | 21.32 | 20.87 | 19.41 | Upgrade
|
| Long-Term Leases | 62.6 | 64.63 | 93.56 | 101.11 | 26.24 | 28.21 | Upgrade
|
| Other Long-Term Liabilities | - | - | 1.05 | 1.11 | 1.11 | 0.15 | Upgrade
|
| Total Liabilities | 90.26 | 89.54 | 126.85 | 123.54 | 48.22 | 47.77 | Upgrade
|
| Common Stock | 0 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | Upgrade
|
| Additional Paid-In Capital | 1,135 | 1,004 | 985.65 | 964.97 | 937.13 | 560.7 | Upgrade
|
| Retained Earnings | -990.17 | -919.78 | -802.61 | -648.08 | -502.54 | -385.03 | Upgrade
|
| Comprehensive Income & Other | -0.27 | -0.47 | -1.53 | -0.71 | -0.26 | -0.73 | Upgrade
|
| Total Common Equity | 144.12 | 83.47 | 181.52 | 316.19 | 434.35 | 174.96 | Upgrade
|
| Shareholders' Equity | 144.12 | 83.47 | 181.52 | 316.19 | 434.35 | 174.96 | Upgrade
|
| Total Liabilities & Equity | 234.38 | 173.01 | 308.37 | 439.73 | 482.57 | 222.73 | Upgrade
|
| Total Debt | 73.26 | 75.04 | 106.8 | 102.99 | 30.71 | 32.35 | Upgrade
|
| Net Cash (Debt) | 79.98 | 21.49 | 78.79 | 202.19 | 399.02 | 133.69 | Upgrade
|
| Net Cash Growth | 92.45% | -72.72% | -61.03% | -49.33% | 198.47% | -34.72% | Upgrade
|
| Net Cash Per Share | 4.68 | 2.13 | 7.94 | 20.62 | 46.86 | 20.86 | Upgrade
|
| Filing Date Shares Outstanding | 20.8 | 20.75 | 10.06 | 9.88 | 9.78 | 7.97 | Upgrade
|
| Total Common Shares Outstanding | 20.8 | 10.14 | 10.01 | 9.84 | 9.75 | 6.73 | Upgrade
|
| Working Capital | 133.42 | 77.86 | 158.35 | 295.83 | 413.57 | 156.46 | Upgrade
|
| Book Value Per Share | 6.93 | 8.23 | 18.13 | 32.14 | 44.53 | 25.99 | Upgrade
|
| Tangible Book Value | 144.12 | 83.47 | 181.52 | 316.19 | 434.35 | 174.96 | Upgrade
|
| Tangible Book Value Per Share | 6.93 | 8.23 | 18.13 | 32.14 | 44.53 | 25.99 | Upgrade
|
| Machinery | 15.86 | 15.51 | 16.58 | 15.14 | 11.21 | 7.72 | Upgrade
|
| Construction In Progress | - | 0.18 | 1.01 | 4.4 | 1.95 | 23.55 | Upgrade
|
| Leasehold Improvements | 13.59 | 13.59 | 34.34 | 26.7 | 24.63 | 1.6 | Upgrade
|
Updated Nov 4, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.